Vistagen Therapeutics, Inc. (VTGN)

Vistagen Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	16.99	30.79	67.13	119.17	16.64	68.14
Short-Term Investments	14.74	14.61	13.35	-	-	-
Cash & Short-Term Investments	31.73	45.4	80.48	119.17	16.64	68.14
Cash Growth	-49.78%	-43.59%	-32.46%	616.23%	-75.58%	-33.92%
Other Receivables	-	-	-	-	-	0.34
Receivables	-	-	-	-	-	0.34
Prepaid Expenses	2.58	1.54	1.59	1.51	0.8	0.2
Other Current Assets	-	-	-	-	0.07	2.33
Total Current Assets	34.31	46.94	82.08	120.67	17.51	71
Property, Plant & Equipment	1.03	1.23	1.81	2.26	2.77	3.08
Long-Term Deferred Charges	0.04	0.06	0.13	-	0.71	0.47
Other Long-Term Assets	0.36	0.34	0.32	0.73	0.1	0.1
Total Assets	35.74	48.56	84.34	123.65	21.09	74.64

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	1	1.54	0.65	1.55	2.47	2.76
Accrued Expenses	9.24	8.76	8.81	2.24	0.8	1.33
Short-Term Debt	-	0.1	-	-	0.11	-
Current Portion of Leases	0.72	0.7	0.56	0.55	0.49	0.43
Current Unearned Revenue	0.23	1.71	2.59	0.79	0.71	1.24
Total Current Liabilities	11.19	12.8	12.61	5.12	4.57	5.77
Long-Term Leases	0.06	0.25	0.95	1.57	2.12	2.61
Long-Term Unearned Revenue	-	-	0.39	2.67	2.32	1.56
Total Liabilities	11.26	13.04	13.95	9.37	9.01	9.93

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	0.04	0.04	0.03	0.03	0.01	0.01
Additional Paid-In Capital	518.76	516.77	481.96	474.44	342.89	336.28
Retained Earnings	-490.35	-477.32	-407.63	-356.21	-326.85	-267.6
Treasury Stock	-3.97	-3.97	-3.97	-3.97	-3.97	-3.97
Comprehensive Income & Other	-0.01	-0	0.01	-	-	-
Total Common Equity	24.48	35.52	70.39	114.29	12.08	64.72
Shareholders' Equity	24.48	35.52	70.39	114.29	12.08	64.72
Total Liabilities & Equity	35.74	48.56	84.34	123.65	21.09	74.64

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	0.78	1.04	1.51	2.12	2.71	3.04
Net Cash (Debt)	30.95	44.36	78.97	117.05	13.93	65.1
Net Cash Growth	-49.12%	-43.83%	-32.53%	740.43%	-78.61%	-34.50%
Net Cash Per Share	0.76	1.17	2.56	6.05	2.00	9.86
Filing Date Shares Outstanding	44.38	41.03	29.16	27.03	7.87	6.89
Total Common Shares Outstanding	44.38	39.62	29	27.03	7.31	6.88
Working Capital	23.12	34.15	69.46	115.55	12.93	65.23
Book Value Per Share	0.55	0.90	2.43	4.23	1.65	9.40
Tangible Book Value	24.48	35.52	70.39	114.29	12.08	64.72
Tangible Book Value Per Share	0.55	0.90	2.43	4.23	1.65	9.40
Machinery	-	1.12	1.6	1.48	1.49	1.45
Leasehold Improvements	-	0.19	0.22	0.21	0.21	0.21

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Jun 15, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 25, 2026

Data Sources Report a data error